Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians

about

Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians

Item

http://www.wikidata.org/entity/Q56968394

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в липні 2018

@uk

name

Using Probability for Patholog ...... ts - a Survey Among Physicians

@en

Using Probability for Pathological Complete Response

@nl

type

Item

label

Using Probability for Patholog ...... ts - a Survey Among Physicians

@en

Using Probability for Pathological Complete Response

@nl

prefLabel

Using Probability for Patholog ...... ts - a Survey Among Physicians

@en

Using Probability for Pathological Complete Response

@nl

P1476

Using Probability for Patholog ...... ts - a Survey Among Physicians

@en

P2093

Alexander Hein

http://www.w3.org/2001/XMLSchema#string

Arndt Hartmann

http://www.w3.org/2001/XMLSchema#string

Carolin C Hack

http://www.w3.org/2001/XMLSchema#string

Christian Jackisch

http://www.w3.org/2001/XMLSchema#string

Christoph Thomssen

http://www.w3.org/2001/XMLSchema#string

Diana Lüftner

http://www.w3.org/2001/XMLSchema#string

Hans-Christian Kolberg

http://www.w3.org/2001/XMLSchema#string

Johannes Ettl

http://www.w3.org/2001/XMLSchema#string

Lothar Häberle

http://www.w3.org/2001/XMLSchema#string

Naiba Nabieva

http://www.w3.org/2001/XMLSchema#string

P2860

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study.

Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment.

Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer.

PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2.

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

P304

707-714

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1055/A-0642-9462

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30057427

http://www.w3.org/2001/XMLSchema#string

P932

6059863

http://www.w3.org/2001/XMLSchema#string